GENGLYCOS

This brand name is authorized in United States.

Active ingredients

The drug GENGLYCOS contains one active pharmaceutical ingredient (API):

1
UNII 7LP92X4WPE - PARIGLASGENE BRECAPARVOVEC
 

Pariglasgene brecaparvovec is an adeno-associated virus serotype 8 (AAV8) based gene therapy designed to deliver a copy of the glucose-6-phosphatase (G6PC) gene with native human G6PC promoter and enhancer elements to hepatocytes, resulting in the production of normally functioning G6Pase.
 
Read more about Pariglasgene brecaparvovec

Medication package inserts

Below package inserts are available for further reading:

Document Type Information Source  
 GENGLYCOS Suspension for intravenous infusion MPI, US: SPL/PLR FDA, National Drug Code (US)

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
US FDA, National Drug Code 69794-332, 69794-333, 69794-334, 69794-335, 69794-336, 69794-337, 69794-338, 69794-339, 69794-340, 69794-341, 69794-342, 69794-343, 69794-344, 69794-345

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈